Todd Alfred Carter Sells 3,525 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Todd Alfred Carter sold 3,525 shares of Voyager Therapeutics stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $3.85, for a total value of $13,571.25. Following the completion of the transaction, the insider directly owned 153,193 shares of the company’s stock, valued at approximately $589,793.05. This trade represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR opened at $3.42 on Friday. Voyager Therapeutics, Inc. has a 1 year low of $2.64 and a 1 year high of $5.55. The business’s 50-day moving average is $4.00 and its 200-day moving average is $4.08. The company has a market capitalization of $190.15 million, a price-to-earnings ratio of -1.58 and a beta of 1.30.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.06. The business had revenue of $11.15 million during the quarter, compared to the consensus estimate of $7.86 million. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%. Analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. HC Wainwright dropped their price objective on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Finally, Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $13.75.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 179.3% in the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after buying an additional 317,927 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Voyager Therapeutics in the 1st quarter valued at about $218,000. Acadian Asset Management LLC lifted its position in Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after acquiring an additional 206,758 shares in the last quarter. Privium Fund Management B.V. boosted its stake in Voyager Therapeutics by 16.6% during the 2nd quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock valued at $79,000 after purchasing an additional 3,596 shares during the last quarter. Finally, Ethic Inc. bought a new stake in Voyager Therapeutics during the 2nd quarter worth approximately $123,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.